404 related articles for article (PubMed ID: 28575060)
1. Increased miltefosine tolerance in clinical isolates of Leishmania donovani is associated with reduced drug accumulation, increased infectivity and resistance to oxidative stress.
Deep DK; Singh R; Bhandari V; Verma A; Sharma V; Wajid S; Sundar S; Ramesh V; Dujardin JC; Salotra P
PLoS Negl Trop Dis; 2017 Jun; 11(6):e0005641. PubMed ID: 28575060
[TBL] [Abstract][Full Text] [Related]
2. Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis.
Bhandari V; Kulshrestha A; Deep DK; Stark O; Prajapati VK; Ramesh V; Sundar S; Schonian G; Dujardin JC; Salotra P
PLoS Negl Trop Dis; 2012; 6(5):e1657. PubMed ID: 22629478
[TBL] [Abstract][Full Text] [Related]
3. Antimony susceptible
Ghosh S; Verma A; Kumar D; Deep DK; Ramesh V; Salotra P; Singh R
Microbiol Spectr; 2024 Jun; 12(6):e0402623. PubMed ID: 38712926
[TBL] [Abstract][Full Text] [Related]
4. Lipase Precursor-Like Protein Promotes Miltefosine Tolerance in Leishmania donovani by Enhancing Parasite Infectivity and Eliciting Anti-inflammatory Responses in Host Macrophages.
Deep DK; Singh R; Kulshrestha A; Wajid S; Salotra P
Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30297367
[TBL] [Abstract][Full Text] [Related]
5. Validation of a simple resazurin-based promastigote assay for the routine monitoring of miltefosine susceptibility in clinical isolates of Leishmania donovani.
Kulshrestha A; Bhandari V; Mukhopadhyay R; Ramesh V; Sundar S; Maes L; Dujardin JC; Roy S; Salotra P
Parasitol Res; 2013 Feb; 112(2):825-8. PubMed ID: 23239091
[TBL] [Abstract][Full Text] [Related]
6. Relapse after treatment with miltefosine for visceral leishmaniasis is associated with increased infectivity of the infecting Leishmania donovani strain.
Rai K; Cuypers B; Bhattarai NR; Uranw S; Berg M; Ostyn B; Dujardin JC; Rijal S; Vanaerschot M
mBio; 2013 Oct; 4(5):e00611-13. PubMed ID: 24105765
[TBL] [Abstract][Full Text] [Related]
7. Laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from India.
Srivastava S; Mishra J; Gupta AK; Singh A; Shankar P; Singh S
Parasit Vectors; 2017 Jan; 10(1):49. PubMed ID: 28137296
[TBL] [Abstract][Full Text] [Related]
8. Phenotypic adaptations of Leishmania donovani to recurrent miltefosine exposure and impact on sand fly infection.
Hendrickx S; Van Bockstal L; Bulté D; Mondelaers A; Aslan H; Rivas L; Maes L; Caljon G
Parasit Vectors; 2020 Feb; 13(1):96. PubMed ID: 32087758
[TBL] [Abstract][Full Text] [Related]
9. Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance.
Rijal S; Ostyn B; Uranw S; Rai K; Bhattarai NR; Dorlo TP; Beijnen JH; Vanaerschot M; Decuypere S; Dhakal SS; Das ML; Karki P; Singh R; Boelaert M; Dujardin JC
Clin Infect Dis; 2013 Jun; 56(11):1530-8. PubMed ID: 23425958
[TBL] [Abstract][Full Text] [Related]
10. Transcriptome profiling identifies genes/pathways associated with experimental resistance to paromomycin in Leishmania donovani.
Verma A; Bhandari V; Deep DK; Sundar S; Dujardin JC; Singh R; Salotra P
Int J Parasitol Drugs Drug Resist; 2017 Dec; 7(3):370-377. PubMed ID: 29035735
[TBL] [Abstract][Full Text] [Related]
11. Miltefosine Resistant Field Isolate From Indian Kala-Azar Patient Shows Similar Phenotype in Experimental Infection.
Khanra S; Sarraf NR; Das AK; Roy S; Manna M
Sci Rep; 2017 Sep; 7(1):10330. PubMed ID: 28871097
[TBL] [Abstract][Full Text] [Related]
12. Antimonial resistance in Leishmania donovani is associated with increased in vivo parasite burden.
Vanaerschot M; De Doncker S; Rijal S; Maes L; Dujardin JC; Decuypere S
PLoS One; 2011; 6(8):e23120. PubMed ID: 21829701
[TBL] [Abstract][Full Text] [Related]
13. In vitro selection of miltefosine resistance in promastigotes of Leishmania donovani from Nepal: genomic and metabolomic characterization.
Shaw CD; Lonchamp J; Downing T; Imamura H; Freeman TM; Cotton JA; Sanders M; Blackburn G; Dujardin JC; Rijal S; Khanal B; Illingworth CJ; Coombs GH; Carter KC
Mol Microbiol; 2016 Mar; 99(6):1134-48. PubMed ID: 26713880
[TBL] [Abstract][Full Text] [Related]
14. Miltefosine resistance in Leishmania donovani involves suppression of oxidative stress-induced programmed cell death.
Mishra J; Singh S
Exp Parasitol; 2013 Oct; 135(2):397-406. PubMed ID: 23968687
[TBL] [Abstract][Full Text] [Related]
15. In vitro susceptibility of Leishmania donovani to miltefosine in Indian visceral leishmaniasis.
Prajapati VK; Sharma S; Rai M; Ostyn B; Salotra P; Vanaerschot M; Dujardin JC; Sundar S
Am J Trop Med Hyg; 2013 Oct; 89(4):750-4. PubMed ID: 23980130
[TBL] [Abstract][Full Text] [Related]
16. Experimental selection of paromomycin and miltefosine resistance in intracellular amastigotes of Leishmania donovani and L. infantum.
Hendrickx S; Boulet G; Mondelaers A; Dujardin JC; Rijal S; Lachaud L; Cos P; Delputte P; Maes L
Parasitol Res; 2014 May; 113(5):1875-81. PubMed ID: 24615359
[TBL] [Abstract][Full Text] [Related]
17. In Vivo Selection of Paromomycin and Miltefosine Resistance in Leishmania donovani and L. infantum in a Syrian Hamster Model.
Hendrickx S; Mondelaers A; Eberhardt E; Delputte P; Cos P; Maes L
Antimicrob Agents Chemother; 2015 Aug; 59(8):4714-8. PubMed ID: 26014955
[TBL] [Abstract][Full Text] [Related]
18. Assessing aquaglyceroporin gene status and expression profile in antimony-susceptible and -resistant clinical isolates of Leishmania donovani from India.
Mandal S; Maharjan M; Singh S; Chatterjee M; Madhubala R
J Antimicrob Chemother; 2010 Mar; 65(3):496-507. PubMed ID: 20067981
[TBL] [Abstract][Full Text] [Related]
19. Visceral and post-Kala-Azar dermal leishmaniasis isolates show significant difference in their in vitro drug susceptibility pattern.
Mishra J; Madhubala R; Singh S
Parasitol Res; 2013 Mar; 112(3):1001-9. PubMed ID: 23242321
[TBL] [Abstract][Full Text] [Related]
20. Lack of correlation between the promastigote back-transformation assay and miltefosine treatment outcome.
Hendrickx S; Eberhardt E; Mondelaers A; Rijal S; Bhattarai NR; Dujardin JC; Delputte P; Cos P; Maes L
J Antimicrob Chemother; 2015 Nov; 70(11):3023-6. PubMed ID: 26253089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]